The U.S. Food and Drug Administration approved Scynexis Inc.’s Brexafemme (ibrexafungerp tablets) as the first oral non-azole treatment for vaginal yeast infections.
Pfizer is expanding the company’s presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and the lead antifungal compound Fosmanogepix (APX001).
Scynexis Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for oral ibrexafungerp for the treatment of vulvovaginal candidiasis.
The deadly fungal infection Candida auris reared its head iin a Los Angeles healthcare facility and could be related to Covid-19 cases through the conservation of personal protective equipment strategies. Amplyx Pharmaceuticals is working to develop a first-line treatment for patients with invasive fungal infections caused by Candida.
Jersey City, N.J.-based SCYNEXIS announced positive results from the biotechnology company’s second interim efficacy analysis of the Phase III open-label FURI study.
Cidara Therapeutics Inc. announced that data from studies of the biotechnology company’s lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR to be held in Houston from Feb. 20-24.
In mid-May, pharma giant Pfizer agreed to buy Anacor Pharmaceuticals for a total transaction value, net of cash, of $5.2 billion. Anacor is a biopharmaceutical company concentrated on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.
January 29, 2016 Dayton, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Voriconazole Tablets, 50 mg and 200 mg. The […]
